Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer

Condition(s) studied

Study summary

Thyroid cancer is the most common endocrine malignancy in the world. Generally, thyroid cancer could be divided into well-differentiated and poorly-differentiated. Well-differentiated thyroid cancers usually have two different patterns, including papillary thyroid cancer and follicular thyroid cancer. Thyroid sonography is convenient to obtain repeatedly for the images of nodular goiter. However, cytology and pathology are still the golden rules to make the final diagnosis. Under the basis of sono-guided fine needle aspiration cytology, diagnosis of papillary thyroid cancer is typically using fine needle aspiration cytology based on the presentation of typical cytologic features. On the other hand, thyroid follicular lesion cannot be interpretated via cytology because the evidence of capsular invasion or vascular permeation of capsule will not be available in fine needle aspiration cytology. Surgical intervention with pathological specimens is the only pathway to make the final diagnosis. Interestingly, both patterns of well-differentiated thyroid cancer shared the same follow-up tumor marker, i.e. serum thyroglobulin. Up to date, pre-operative diagnosis of follicular thyroid cancer is still one of the unresolved issues in endocrine oncology.

Eligibility

Primary outcome measure(s)

• Change of serum thyroglobulin level — Within 36 months
  Thyroid function test
• Change of serum free T4 level — Within 36 months
  Thyroid function test
• Change of serum TSH level — Within 36 months
  Thyroid function test
• Change of anti-thyroglobulin level — Within 36 months
  Thyroid function test
• Urinary exosomal thyroglobulin detection — Within 36 months
  Urinary exosomal biomarker
• Urinary exosomal galectin-3 detection — Within 36 months
  Urinary exosomal biomarker
• Urinary exosomal calprotectin A9 detection — Within 36 months
  Urinary exosomal biomarker
• Urinary exosomal transketolase detection — Within 36 months
  Urinary exosomal biomarker
• Urinary exosomal keratin 19 detection — Within 36 months
  Urinary exosomal biomarker
• Urinary exosomal angiopoietin-1 detection — Within 36 months
  Urinary exosomal biomarker
• Urinary exosomal tissue inhibitor of metalloproteinase detection — Within 36 months
  Urinary exosomal biomarker
• Urinary exosomal keratin 8 detection — Within 36 months
  Urinary exosomal biomarker
• Urinary exosomal calprotectin A8 detection — Within 36 months
  Urinary exosomal biomarker
• Urinary exosomal annexin II detection — Within 36 months
  Urinary exosomal biomarker
• Urinary exosomal afamin detection — Within 36 months
  Urinary exosomal biomarker

Trial sites (1)

More National Taiwan University Hospital trials in Taiwan

Other trials for the same condition